MedTrace Logo

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-05-11

No results posted yet for this study

Summary

Safe and independent mobility at home and in the community requires control of walking while accomplishing other functional tasks. A hallmark of healthy control of walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding executive resources \[1\]. Recent evidence indicates that walking disorders are often characterized by a shift in the locomotor control strategy from healthy automaticity to compensatory executive control. This shift is potentially detrimental to walking performance as an executive control strategy is not optimized for locomotor control and it places excessive demands on a limited pool of cognitive reserve.

Here, the investigators hypothesize that walking automaticity, as measured by the prefrontal cortex activity while walking, will be improved by donepezil (a cholinesterase inhibitor).

Conditions

  • Parkinson Disease

Interventions

DRUG

Donepezil

Donepezil 5 mg per day for week 1-2 or 5-6

DRUG

Placebo

Placebo 5 mg per day for week 1-2 or 5-6

Sponsors & Collaborators

  • Medical Research Foundation, Oregon

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Martina Mancini, PhD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2019-05-30
Completion
2019-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03599726 on ClinicalTrials.gov